CN104822658B - 作为多种激酶抑制剂的稠合三环酰胺类化合物 - Google Patents
作为多种激酶抑制剂的稠合三环酰胺类化合物 Download PDFInfo
- Publication number
- CN104822658B CN104822658B CN201480003286.7A CN201480003286A CN104822658B CN 104822658 B CN104822658 B CN 104822658B CN 201480003286 A CN201480003286 A CN 201480003286A CN 104822658 B CN104822658 B CN 104822658B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- formula
- piperidinyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *N(*)*1CC1 Chemical compound *N(*)*1CC1 0.000 description 24
- PBOVWBPDPHPCSN-IUODEOHRSA-N O=C(CC1)Nc2c1c(Oc1ccc3O[C@H](C4)[C@H]4c3c1)ccn2 Chemical compound O=C(CC1)Nc2c1c(Oc1ccc3O[C@H](C4)[C@H]4c3c1)ccn2 PBOVWBPDPHPCSN-IUODEOHRSA-N 0.000 description 3
- YOTNCSZEAXNVQY-UHFFFAOYSA-N C1[C@]2(C3)C1C[U][C@H]3C2 Chemical compound C1[C@]2(C3)C1C[U][C@H]3C2 YOTNCSZEAXNVQY-UHFFFAOYSA-N 0.000 description 1
- VCPSMSCGUVFAMY-UHFFFAOYSA-N CC(C)(C)OC(NC(C)(C)c1cc(C(O)=O)cc(C(F)(F)F)c1)=O Chemical compound CC(C)(C)OC(NC(C)(C)c1cc(C(O)=O)cc(C(F)(F)F)c1)=O VCPSMSCGUVFAMY-UHFFFAOYSA-N 0.000 description 1
- ISVOWLDLLDVTBL-UHFFFAOYSA-N CC(C)(C)OC(NC1(CCC1)c1cc(C(F)(F)F)cc(C(N)=O)c1)=O Chemical compound CC(C)(C)OC(NC1(CCC1)c1cc(C(F)(F)F)cc(C(N)=O)c1)=O ISVOWLDLLDVTBL-UHFFFAOYSA-N 0.000 description 1
- GGSCEHBCNHNFRH-HQVZTVAUSA-N CC(C1)[C@H]1c1cc(Oc2ccnc(N3)c2CCC3=O)ccc1O Chemical compound CC(C1)[C@H]1c1cc(Oc2ccnc(N3)c2CCC3=O)ccc1O GGSCEHBCNHNFRH-HQVZTVAUSA-N 0.000 description 1
- JXSXWJXLUDCRDF-RQFHIDMOSA-N CCC(CC1)Nc2c1c(Oc1ccc3O[C@@H]([C@@H]4C(O)O)[C@@H]4c3c1)ccc2CC Chemical compound CCC(CC1)Nc2c1c(Oc1ccc3O[C@@H]([C@@H]4C(O)O)[C@@H]4c3c1)ccc2CC JXSXWJXLUDCRDF-RQFHIDMOSA-N 0.000 description 1
- MWBBOIJIWIGAGC-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2C(C)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2C(C)=O)CC1 MWBBOIJIWIGAGC-UHFFFAOYSA-N 0.000 description 1
- NALCAYIRNHHHGC-GMTAPVOTSA-N CCOC([C@H]([C@H]1c2c3)[C@@H]1Oc2ccc3O)=O Chemical compound CCOC([C@H]([C@H]1c2c3)[C@@H]1Oc2ccc3O)=O NALCAYIRNHHHGC-GMTAPVOTSA-N 0.000 description 1
- HDNRAPAFJLXKBV-UHFFFAOYSA-N CCc(cc1)ccc1OC Chemical compound CCc(cc1)ccc1OC HDNRAPAFJLXKBV-UHFFFAOYSA-N 0.000 description 1
- WLDWXOWCOUCKLU-GFCCVEGCSA-N CN(C)[C@H](CCC1)CN1C(C(C(F)(F)F)=C1)=CCC=C1C(N)=O Chemical compound CN(C)[C@H](CCC1)CN1C(C(C(F)(F)F)=C1)=CCC=C1C(N)=O WLDWXOWCOUCKLU-GFCCVEGCSA-N 0.000 description 1
- ZIGKSCVRCRCHRS-UHFFFAOYSA-N CN1CCN(Cc(c(C(F)(F)F)c2)ccc2C(N)=O)CC1 Chemical compound CN1CCN(Cc(c(C(F)(F)F)c2)ccc2C(N)=O)CC1 ZIGKSCVRCRCHRS-UHFFFAOYSA-N 0.000 description 1
- APUFKCFIZMPPEP-UHFFFAOYSA-N CNC1(CC1)C1=CC(CN)CC(C(F)(F)F)=C1 Chemical compound CNC1(CC1)C1=CC(CN)CC(C(F)(F)F)=C1 APUFKCFIZMPPEP-UHFFFAOYSA-N 0.000 description 1
- IRYBOHVMFKZODT-UHFFFAOYSA-N COC(c(cc1C(F)(F)F)ccc1F)=O Chemical compound COC(c(cc1C(F)(F)F)ccc1F)=O IRYBOHVMFKZODT-UHFFFAOYSA-N 0.000 description 1
- CHJZZYDOCDJKFY-UHFFFAOYSA-N COC(c1cc(Br)cc(C(F)(F)F)c1)=O Chemical compound COC(c1cc(Br)cc(C(F)(F)F)c1)=O CHJZZYDOCDJKFY-UHFFFAOYSA-N 0.000 description 1
- DSIYKUURMQSAAK-HKWQLCKISA-N C[C@H]1O[C@@H](C)CN(Cc(c(C(F)(F)F)c2)ccc2C(N[C@H]([C@@H]2c3c4)[C@H]2Oc3ccc4Oc2c(CCC(N3)=O)c3ncc2)=O)C1 Chemical compound C[C@H]1O[C@@H](C)CN(Cc(c(C(F)(F)F)c2)ccc2C(N[C@H]([C@@H]2c3c4)[C@H]2Oc3ccc4Oc2c(CCC(N3)=O)c3ncc2)=O)C1 DSIYKUURMQSAAK-HKWQLCKISA-N 0.000 description 1
- XKQMUBZLWVCRQI-QBGWAWDMSA-N Cc1cc(C(NC([C@@H]2c3c4)[C@H]2Oc3ccc4Oc2c(CCC(N3)=O)c3ncc2)=O)ccc1CN1CCN(C)CC1 Chemical compound Cc1cc(C(NC([C@@H]2c3c4)[C@H]2Oc3ccc4Oc2c(CCC(N3)=O)c3ncc2)=O)ccc1CN1CCN(C)CC1 XKQMUBZLWVCRQI-QBGWAWDMSA-N 0.000 description 1
- HMVFVZUKYMWMHO-UHFFFAOYSA-N N#Cc1cc(C(F)(F)F)cc([Ar])c1 Chemical compound N#Cc1cc(C(F)(F)F)cc([Ar])c1 HMVFVZUKYMWMHO-UHFFFAOYSA-N 0.000 description 1
- XSMRRJXIDVNINP-UHFFFAOYSA-N NC(c1cccc(C(F)(F)F)n1)=O Chemical compound NC(c1cccc(C(F)(F)F)n1)=O XSMRRJXIDVNINP-UHFFFAOYSA-N 0.000 description 1
- LPOXCHABLAZUHB-VXNXHJTFSA-N NC1(CC1)c1cc(C(F)(F)F)cc(C(N[C@H]([C@@H]2c3c4)[C@H]2Oc3ccc4Oc2c(CCC(N3)=O)c3ncc2)=O)c1 Chemical compound NC1(CC1)c1cc(C(F)(F)F)cc(C(N[C@H]([C@@H]2c3c4)[C@H]2Oc3ccc4Oc2c(CCC(N3)=O)c3ncc2)=O)c1 LPOXCHABLAZUHB-VXNXHJTFSA-N 0.000 description 1
- NOGFPJHXTCXVDA-UHFFFAOYSA-N O=C(CC1)Nc2c1c(F)ccn2 Chemical compound O=C(CC1)Nc2c1c(F)ccn2 NOGFPJHXTCXVDA-UHFFFAOYSA-N 0.000 description 1
- LHOZLTPSXOGILJ-WPBUFGDCSA-N O=C(CC1)Nc2c1c(OC(C1)=CC=C3C1[C@@H](C1)C1C3)ccn2 Chemical compound O=C(CC1)Nc2c1c(OC(C1)=CC=C3C1[C@@H](C1)C1C3)ccn2 LHOZLTPSXOGILJ-WPBUFGDCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201480003286.7A CN104822658B (zh) | 2013-06-28 | 2014-06-27 | 作为多种激酶抑制剂的稠合三环酰胺类化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/078317 | 2013-06-28 | ||
| CN2013078317 | 2013-06-28 | ||
| PCT/CN2014/080986 WO2014206344A1 (en) | 2013-06-28 | 2014-06-27 | Fused tricyclic amide compounds as multiple kinase inhibitors |
| CN201480003286.7A CN104822658B (zh) | 2013-06-28 | 2014-06-27 | 作为多种激酶抑制剂的稠合三环酰胺类化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104822658A CN104822658A (zh) | 2015-08-05 |
| CN104822658B true CN104822658B (zh) | 2017-08-08 |
Family
ID=52141107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480003286.7A Expired - Fee Related CN104822658B (zh) | 2013-06-28 | 2014-06-27 | 作为多种激酶抑制剂的稠合三环酰胺类化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9670231B2 (enExample) |
| EP (1) | EP3013797B1 (enExample) |
| JP (2) | JP6380862B2 (enExample) |
| CN (1) | CN104822658B (enExample) |
| WO (1) | WO2014206344A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| EP3145911B1 (en) | 2014-05-21 | 2020-07-08 | Solvay Specialty Polymers USA, L.L.C. | Stabilizer compounds |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI804987B (zh) * | 2015-12-24 | 2023-06-11 | 日商協和麒麟股份有限公司 | α、β不飽和醯胺化合物 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US11266624B2 (en) * | 2018-04-03 | 2022-03-08 | Texas Tech University System | CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| CN111484490B (zh) * | 2019-01-25 | 2024-07-09 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US20230046018A1 (en) * | 2019-12-06 | 2023-02-16 | Medshine Discovery Inc. | Biaryl compound as pan-raf kinase inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN113912591B (zh) * | 2020-07-08 | 2023-10-20 | 齐鲁制药有限公司 | 联芳基化合物 |
| US20250195533A1 (en) * | 2020-12-11 | 2025-06-19 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| WO2023125787A1 (en) * | 2021-12-31 | 2023-07-06 | Edigene Therapeutics (Beijing) Inc. | Biomarkers for colorectal cancer treatment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067444A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| WO2007136572A2 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100733D0 (sv) | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| KR20050033663A (ko) * | 2002-09-05 | 2005-04-12 | 메디비르 아베 | 비-뉴클레오시드 역전사효소 억제제 |
| JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ｒｅｔ調節剤の開発のための化合物および方法 |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| US7566716B2 (en) | 2005-05-20 | 2009-07-28 | Array Biopharma Inc. | Imidazopyrazines as Raf inhibitor compounds |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| AU2006284751A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| BRPI0716477A2 (pt) | 2006-09-06 | 2014-03-18 | Hoffmann La Roche | Derivados heteroarila como inibidores de quinase protéica |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| AU2011209234B2 (en) | 2010-01-27 | 2015-05-07 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| WO2011097526A1 (en) | 2010-02-05 | 2011-08-11 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
-
2014
- 2014-06-27 WO PCT/CN2014/080986 patent/WO2014206344A1/en not_active Ceased
- 2014-06-27 US US14/901,556 patent/US9670231B2/en not_active Expired - Fee Related
- 2014-06-27 CN CN201480003286.7A patent/CN104822658B/zh not_active Expired - Fee Related
- 2014-06-27 EP EP14816633.3A patent/EP3013797B1/en not_active Not-in-force
- 2014-06-27 JP JP2016522233A patent/JP6380862B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-19 JP JP2018135872A patent/JP2018184439A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067444A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| WO2007136572A2 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016523270A (ja) | 2016-08-08 |
| US20160159820A1 (en) | 2016-06-09 |
| HK1210166A1 (en) | 2016-04-15 |
| CN104822658A (zh) | 2015-08-05 |
| JP6380862B2 (ja) | 2018-08-29 |
| EP3013797A1 (en) | 2016-05-04 |
| US9670231B2 (en) | 2017-06-06 |
| WO2014206344A1 (en) | 2014-12-31 |
| EP3013797A4 (en) | 2016-12-07 |
| EP3013797B1 (en) | 2018-01-03 |
| JP2018184439A (ja) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104822658A (zh) | 作为多种激酶抑制剂的稠合三环酰胺类化合物 | |
| JP7207629B2 (ja) | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 | |
| CN104884458B (zh) | 作为蛋白质激酶抑制剂的稠合杂环化合物 | |
| CN103703004B (zh) | 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮 | |
| TWI698435B (zh) | 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶 | |
| CN102459187B (zh) | Janus激酶抑制化合物和方法 | |
| JP5868521B2 (ja) | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 | |
| CN102224152B (zh) | 吡唑并吡啶pi3k抑制剂化合物及使用方法 | |
| CN106083849A (zh) | 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物 | |
| CN105348299B (zh) | 作为raf激酶抑制剂的稠合三环化合物 | |
| TWI640518B (zh) | 作爲ｒａｆ激酶抑制劑的稠合三環化合物 | |
| HK1210166B (en) | Fused tricyclic amide compounds as multiple kinase inhibitors | |
| JP6175519B2 (ja) | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 | |
| KR20160040182A (ko) | 다중 키나제억제제인 융합된 트리사이클릭 아미드 화합물 | |
| HK1263053A1 (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| HK1244787B (en) | 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE, TRYPTOPHANE DIOXYGENASE INHIBITOR | |
| HK40014846A (en) | Novel 8-substituted imidazo[1, 5-a] pyridines as ido1 and/or tdo inhibitor | |
| HK1217485B (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| HK1221222B (en) | Fused tricyclic compounds as raf kinase inhibitors | |
| HK1192232B (en) | Fused tricyclic compounds as raf kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1210166 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1210166 Country of ref document: HK |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190618 Address after: Floor 1-2, Building 1, 30th Academy of Science Park Road, Changping District, Beijing Patentee after: Baiji Shenzhou (Beijing) Biotechnology Co.,Ltd. Address before: Cayman Islands Grand Cayman Patentee before: BEIGENE, Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170808 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |